EGFR kinase inhibitors that are approved for NSCLC with EGFR L858R mutations or exon 19 deletions are ineffective in the vast majority of EGFR exon 20 insertion mutant NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.